skip to content
Buprenorphine formulations for the treatment of opioid use disorders : a review of comparative clinical effectiveness, cost-effectiveness and guidelines Preview this item
ClosePreview this item
Checking...

Buprenorphine formulations for the treatment of opioid use disorders : a review of comparative clinical effectiveness, cost-effectiveness and guidelines

Author: Sharada Harricharan; Kelly Farrah; Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, July 31, 2017.
Series: Rapid response report (Canadian Agency for Drugs and Technologies in Health)
Edition/Format:   eBook : Document : English : Version 1.0View all editions and formats
Summary:
Currently, buprenorphine formulations for the treatment of opioid use disorder (OUD) include an implant, as well as oral formulations combined with an opioid antagonist, naloxone. This combination is designed to discourage abuse of buprenorphine, as naloxone can precipitate withdrawal symptoms in patients with OUD. Buprenorphine-naloxone combination formulations include a sublingual tablet, sublingual film, and  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Review
Electronic books
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Sharada Harricharan; Kelly Farrah; Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1001214790
Description: 1 online resource (1 PDF file (32 pages)) : illustrations.
Series Title: Rapid response report (Canadian Agency for Drugs and Technologies in Health)
Responsibility: Sharada Harricharan, Kelly Farrah.
More information:

Abstract:

Currently, buprenorphine formulations for the treatment of opioid use disorder (OUD) include an implant, as well as oral formulations combined with an opioid antagonist, naloxone. This combination is designed to discourage abuse of buprenorphine, as naloxone can precipitate withdrawal symptoms in patients with OUD. Buprenorphine-naloxone combination formulations include a sublingual tablet, sublingual film, and high-bioavailability sublingual tablet. Only the sublingual tablet formulation of the buprenorphine-naloxone combination (Suboxone) is licensed for use in Canada. On 21 April 2017, Health Canada proposed to allow the importation and use of medications that have been authorized for sale in the United States, European Union or Switzerland, but are not yet authorized in Canada. Once this process is implemented, this medication list could potentially include newer buprenorphine formulations available in the US. The purpose of this report is to evaluate the clinical effectiveness, cost-effectiveness and evidence-based guidelines for the use of newer and unique buprenorphine formulations in patients with OUD.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1001214790> # Buprenorphine formulations for the treatment of opioid use disorders : a review of comparative clinical effectiveness, cost-effectiveness and guidelines
    a schema:MediaObject, schema:CreativeWork, schema:Book ;
    library:oclcnum "1001214790" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/health_sciences> ; # Health sciences
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/buprenorphine_naloxone> ; # Buprenorphine/naloxone
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/medicine> ; # Medicine
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/political_planning> ; # Political planning
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/comparative_effectiveness_research> ; # Comparative Effectiveness Research
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/randomized_controlled_trial> ; # Randomized controlled trial
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/opioid> ; # Opioid
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Place/canada> ; # Canada.
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/substance_abuse> ; # Substance abuse
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/political_planning_canada> ; # Political planning--Canada
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/cost_benefit_analysis> ; # Cost-Benefit Analysis
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/guidelines_as_topic> ; # Guidelines as Topic
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/opioid_related_disorders_drug_therapy> ; # Opioid-Related Disorders--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/buprenorphine_naloxone_drug_combination_therapeutic_use> ; # Buprenorphine, Naloxone Drug Combination--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/buprenorphine> ; # Buprenorphine
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/health_care> ; # Health care
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/health> ; # Health
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/treatment_outcome> ; # Treatment Outcome
    schema:about <http://experiment.worldcat.org/entity/work/data/4461339774#Topic/opioid_use_disorder> ; # Opioid use disorder
    schema:author <http://experiment.worldcat.org/entity/work/data/4461339774#Person/harricharan_sharada> ; # Sharada Harricharan
    schema:author <http://experiment.worldcat.org/entity/work/data/4461339774#Person/farrah_kelly> ; # Kelly Farrah
    schema:bookEdition "Version 1.0." ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/4461339774#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2017" ;
    schema:description "Currently, buprenorphine formulations for the treatment of opioid use disorder (OUD) include an implant, as well as oral formulations combined with an opioid antagonist, naloxone. This combination is designed to discourage abuse of buprenorphine, as naloxone can precipitate withdrawal symptoms in patients with OUD. Buprenorphine-naloxone combination formulations include a sublingual tablet, sublingual film, and high-bioavailability sublingual tablet. Only the sublingual tablet formulation of the buprenorphine-naloxone combination (Suboxone) is licensed for use in Canada. On 21 April 2017, Health Canada proposed to allow the importation and use of medications that have been authorized for sale in the United States, European Union or Switzerland, but are not yet authorized in Canada. Once this process is implemented, this medication list could potentially include newer buprenorphine formulations available in the US. The purpose of this report is to evaluate the clinical effectiveness, cost-effectiveness and evidence-based guidelines for the use of newer and unique buprenorphine formulations in patients with OUD."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/4461339774> ;
    schema:genre "Electronic books"@en ;
    schema:genre "Review"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://worldcat.org/issn/1922-8147> ; # Rapid response report (Canadian Agency for Drugs and Technologies in Health)
    schema:name "Buprenorphine formulations for the treatment of opioid use disorders : a review of comparative clinical effectiveness, cost-effectiveness and guidelines"@en ;
    schema:productID "1001214790" ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK525042/> ;
    schema:url <https://www.ncbi.nlm.nih.gov/books/NBK525042> ;
    schema:url <https://www.cadth.ca/sites/default/files/pdf/htis/2017/RC0908%20Buprenorphine%20Formulations%20Final.pdf> ;
    schema:url <http://www.deslibris.ca/ID/10091836> ;
    schema:url <https://www.deslibris.ca/ID/10091836> ;
    schema:url <http://books.scholarsportal.info/viewdoc.html?id=/ebooks/ebooks0/gibson_cppc-chrc/2017-10-02/9/10091836> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1001214790> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/4461339774#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Person/farrah_kelly> # Kelly Farrah
    a schema:Person ;
    schema:familyName "Farrah" ;
    schema:givenName "Kelly" ;
    schema:name "Kelly Farrah" ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Person/harricharan_sharada> # Sharada Harricharan
    a schema:Person ;
    schema:familyName "Harricharan" ;
    schema:givenName "Sharada" ;
    schema:name "Sharada Harricharan" ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/buprenorphine_naloxone> # Buprenorphine/naloxone
    a schema:Intangible ;
    schema:name "Buprenorphine/naloxone"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/buprenorphine_naloxone_drug_combination_therapeutic_use> # Buprenorphine, Naloxone Drug Combination--therapeutic use
    a schema:Intangible ;
    schema:name "Buprenorphine, Naloxone Drug Combination--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/comparative_effectiveness_research> # Comparative Effectiveness Research
    a schema:Intangible ;
    schema:name "Comparative Effectiveness Research"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/cost_benefit_analysis> # Cost-Benefit Analysis
    a schema:Intangible ;
    schema:name "Cost-Benefit Analysis"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/guidelines_as_topic> # Guidelines as Topic
    a schema:Intangible ;
    schema:name "Guidelines as Topic"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/opioid_related_disorders_drug_therapy> # Opioid-Related Disorders--drug therapy
    a schema:Intangible ;
    schema:name "Opioid-Related Disorders--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/opioid_use_disorder> # Opioid use disorder
    a schema:Intangible ;
    schema:name "Opioid use disorder"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/political_planning> # Political planning
    a schema:Intangible ;
    schema:name "Political planning"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/political_planning_canada> # Political planning--Canada
    a schema:Intangible ;
    schema:name "Political planning--Canada"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/randomized_controlled_trial> # Randomized controlled trial
    a schema:Intangible ;
    schema:name "Randomized controlled trial"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4461339774#Topic/treatment_outcome> # Treatment Outcome
    a schema:Intangible ;
    schema:name "Treatment Outcome"@en ;
    .

<http://worldcat.org/issn/1922-8147> # Rapid response report (Canadian Agency for Drugs and Technologies in Health)
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1001214790> ; # Buprenorphine formulations for the treatment of opioid use disorders : a review of comparative clinical effectiveness, cost-effectiveness and guidelines
    schema:issn "1922-8147" ;
    schema:name "Rapid response report (Canadian Agency for Drugs and Technologies in Health)" ;
    schema:name "CADTH rapid response report: summary with critical appraisal," ;
    .

<http://www.worldcat.org/title/-/oclc/1001214790>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/1001214790> ; # Buprenorphine formulations for the treatment of opioid use disorders : a review of comparative clinical effectiveness, cost-effectiveness and guidelines
    schema:dateModified "2019-05-11" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.